Lilly, US govt sign deal for 600,000 doses of Covid-19 drug bebtelovimab

Eli Lilly and Company (Lilly) has signed a deal worth at least $720 million with the US government to deliver up to 600,000 doses of bebtelovimab, its investigational drug for Covid-19.

According to Lilly, the US government will accept the doses of bebtelovimab if it secures an emergency use authorization (EUA) from the US Food and Drug Administration (FDA).

The US pharma giant is seeking a EUA for bebtelovimab from the FDA for the treatment of mild to moderate Covid-19 in certain high-risk patients.

Under the supply deal, Lilly will have to deliver the doses no later than 31 March 2022 with an option of supplying 500,000 additional doses no later than 31 July 2022.